Does TAFASITAMAB Cause Poor venous access? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Poor venous access have been filed in association with TAFASITAMAB (MONJUVI). This represents 0.4% of all adverse event reports for TAFASITAMAB.
6
Reports of Poor venous access with TAFASITAMAB
0.4%
of all TAFASITAMAB reports
0
Deaths
1
Hospitalizations
How Dangerous Is Poor venous access From TAFASITAMAB?
Of the 6 reports, 1 (16.7%) required hospitalization.
Is Poor venous access Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TAFASITAMAB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Poor venous access?
VEDOLIZUMAB (1,043)
INFLIXIMAB (917)
INFLIXIMAB-DYYB (782)
ECULIZUMAB (555)
HUMAN IMMUNOGLOBULIN G (504)
NATALIZUMAB (422)
RITUXIMAB (299)
TOCILIZUMAB (287)
METHOTREXATE (257)
ABATACEPT (249)
Which TAFASITAMAB Alternatives Have Lower Poor venous access Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR